Cipla has announced the formation of a strategic joint venture with Kemwell Biopharma Private Limited, marking a significant expansion into the biologics segment. The partnership represents a major investment commitment with both companies planning to invest up to ₹100 million in their respective ownership ratios.

Joint Venture Structure

The companies have established a 60:40 partnership arrangement for incorporating a joint venture company in India:

Strategic Partnership Details

Both partners will invest up to ₹100 million in the joint venture company according to their respective ownership ratios. This substantial investment commitment reflects the strategic importance of the biologics segment for both companies.

The joint venture will undertake comprehensive biologics operations including developing, applying for and obtaining licenses, manufacturing, commercializing, importing and exporting biologic products, as well as licensing or outsourcing these activities.

Partner Capabilities

Kemwell Biopharma brings significant expertise as a premier Asia-based biologics Contract Development and Manufacturing Organization (CDMO). The company operates an end-to-end service platform for global biopharma clients through its Bangalore cGMP site, which is certified by the US FDA.

Business Objectives

The joint venture company is being incorporated with the objective to develop, manufacture and commercialize biologics for global markets. This collaboration positions both partners to capitalize on the growing biologics market segment by combining Cipla's established pharmaceutical market presence with Kemwell's specialized biologics manufacturing capabilities.

Kemwell supports both commercial manufacturing and research and development programs for novel biologics and biosimilars, making it an ideal partner for Cipla's biologics expansion strategy.

Cipla Limited has announced the incorporation of a new wholly owned subsidiary in the Kingdom of Saudi Arabia, marking a strategic expansion into the Middle Eastern pharmaceutical market. The company informed stock exchanges on 2nd March, 2026, about the establishment of 'Cipla Middle East Company' effective 1st March, 2026.

Subsidiary Structure and Incorporation Details

The new subsidiary was incorporated by Cipla (EU) Limited, UK, which is itself a wholly owned subsidiary of Cipla Limited. This creates a step-down subsidiary structure for the company's Middle Eastern operations.

Business Objectives and Strategic Purpose

Cipla Middle East Company has been incorporated with specific objectives aligned with the pharmaceutical industry. The subsidiary will focus on:

• Manufacturing pharmaceutical products in Saudi Arabia
• Distribution of pharmaceutical products across the region
• Holding marketing authorizations in the Kingdom of Saudi Arabia

The establishment of this subsidiary represents Cipla's commitment to expanding its presence in the Middle Eastern pharmaceutical market and establishing local manufacturing capabilities.

Regulatory Compliance and Disclosure

The incorporation was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required by SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

Market Expansion Strategy

The incorporation of Cipla Middle East Company demonstrates the company's strategic approach to international expansion. By establishing a local entity in Saudi Arabia, Cipla positions itself to better serve the Middle Eastern pharmaceutical market while maintaining compliance with local regulatory requirements.

As a newly incorporated entity, the subsidiary currently has no applicable turnover or historical financial data. The focus remains on establishing operational capabilities and securing necessary regulatory approvals for pharmaceutical manufacturing and distribution activities in the Kingdom of Saudi Arabia.